Consensus OncoCyte Corporation

Equities

OCX

US68235C2061

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
2.455 ^USD	-2.19%		-10.73%	-1.80%

Apr. 16	Broadwood Capital, Inc. Engages with OncoCyte Corporation	CI
Apr. 12	Sector Update: Health Care Stocks Steady Pre-Bell Friday	MT

Evolution of the average Target Price on OncoCyte Corporation

Price target over the last 5 years

History of analyst recommendation changes

785fdc737288706f097.MsIVylAbvAk2JaXkNMAgnBTrI2VCZkQx45tS-zRwm4k.faNZvD1i_05VEMKiQKMR9VjcYlwjHCplgeFiim4H0cxCh1OaHUPFP3Noyg~e3a46e6e0488a4fbd96ea7501e2435e5

Analyst Recommendations on OncoCyte Corporation

Needham Adjusts Price Target on OncoCyte to $3.60 From $4.25, Maintains Buy Rating	Nov. 09	MT
Benchmark Adjusts Price Target on OncoCyte to $5 From $9, Maintains Speculative Buy Rating	23-08-24	MT
Piper Sandler Adjusts Price Target on OncoCyte to $3.50 From $6, Keeps Neutral Rating	23-08-15	MT
Needham Adjusts OncoCyte's Price Target to $4.25 From $9, Keeps Buy Rating	23-08-10	MT
Needham Trims Price Target on OncoCyte to $0.45 From $1.40, Keeps Buy Rating	23-04-04	MT
Lake Street Downgrades Oncocyte to Hold From Buy, Cuts Price Target to $0.50 From $3	22-12-01	MT
Piper Sandler Downgrades OncoCyte to Neutral From Overweight, Adjusts Price Target to $0.50 From $1	22-11-18	MT
Piper Sandler Trims Price Target on OncoCyte to $1 From $1.50, Maintains Overweight Rating	22-11-14	MT
Lake Street Adjusts OncoCyte Price Target to $3 From $6, Maintains Buy Rating	22-08-11	MT
Needham Trims OncoCyte's Price Target to $2.10 From $2.25 on 'Lower Revenue Estimates;' Buy Rating Kept	22-08-11	MT
Stephens Downgrades OncoCyte to Equalweight From Overweight, Adjusts Price Target to $1.25 From $2	22-05-24	MT
Piper Sandler Trims OncoCyte's Price Target to $1.40 From $1.80, Maintains Overweight Rating	22-05-16	MT
Needham Adjusts OncoCyte's Price Target to $2.25 From $4 on 'Peer Multiple Compression,' Reiterates Buy Rating	22-05-12	MT
Piper Sandler Adjusts OncoCyte's Price Target to $1.80 from $3.10, Keeps Overweight Rating	22-03-18	MT
KeyBanc Downgrades OncoCyte to Sector Weight From Overweight, Citing Need for Added Capital, Removes $7 Price Target	22-03-14	MT
Lake Street Adjusts OncoCyte Price Target to $6 From $11, Maintains Buy Rating	22-03-11	MT
Needham Adjusts OncoCyte's Price Target to $4 From $5, Citing Peer Multiple Compression; Buy Rating Kept	22-03-11	MT
Stephens Initiates OncoCyte With Overweight Rating, $3.10 Price Target	22-01-07	MT
Stephens Starts OncoCyte at Overweight With $3.10 Price Target	22-01-07	MT
Needham Lowers OncoCyte's Price Target to $5 From $7, Maintains Buy Rating	21-12-15	MT
Needham Cuts OncoCyte's Price Target to $7 From $8 on Lower Revenue Estimates; Buy Rating Kept	21-11-10	MT
ONCOCYTE : Chardan Suspends Coverage on OncoCyte at Neutral Rating With $2 Price Target	21-08-02	MT
ONCOCYTE : Needham Assumes OncoCyte at Buy with $8 Price Target	21-03-17	MT
ONCOCYTE : Piper Sandler Upgrades OncoCyte to Overweight From Neutral, Adjusts Price Target to $4 From $2	20-12-16	MT
ONCOCYTE : BTIG Starts OncoCyte at Buy With $5 Price Target	20-11-30	MT